Nightingale Health: Into the IFRS world before the half-year report
By Antti Luiro
We lowered our profitability estimates in connection with the IFRS transition after reviewing the level of fixed costs required by the company in the next few years. However, in the big picture, the company's story has not changed. In the forthcoming half-year report, we look in particular for signs of potential commercial advances.
Nightingale Health
1.19
1.3
Reduce
Reduce
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Read more on company pageKey Estimate Figures2023-03-16
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 2.3 | 2.9 | 4.9 |
growth-% | 0.35 % | 24.44 % | 70.00 % |
EBIT (adj.) | -13.6 | -16.5 | -14.9 |
EBIT-% (adj.) | -589.45 % | -573.13 % | -304.10 % |
EPS (adj.) | -0.27 | -0.28 | -0.25 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | 3.07 | - | - |